J. Clin. Med., Volume 10, Issue 4 (February-2 2021) – 339 articles
Cover Story (view full-size image): The clot-stabilizing effect and downstream functionalities of coagulation factor XIII (FXIII) make it a promising target for drug development since FXIII inhibition does not significantly increase the bleeding risk. To investigate the inhibitory effect of aptamers on activated FXIII (FXIIIa), six DNA aptamers targeting FXIIIa were selected and characterized. Among all, the so-called FA12 aptamer showed inhibitoy effect on incorporation of FXIIIa and α2-antiplasmin (α2AP) to fibrin. Furthermore, FA12 reduced the clot stiffness and elasticity in ROTEM analysis when spiked to citrated plasma or whole blood. These features render FA12 as an interesting candidate molecule for the development of FXIIIa-targeting therapeutic strategies. View this paper
- Issues are regarded as officially published after their release is announced to the table of contents alert mailing list.
- You may sign up for e-mail alerts to receive table of contents of newly released issues.
- PDF is the official format for papers published in both, html and pdf forms. To view the papers in pdf format, click on the "PDF Full-text" link, and use the free Adobe Reader to open them.